Central regions | Technology & innovation

Russian developer releases vaccine for three diseases

27 Jul '18
Microgen, a Russian biotech company which is part of the Natsimbio holding firm, has completed the development of a new combinatory vaccine for measles, rubella and parotitis (mumps). The Vactrivir is expected to protect people against the three dangerous diseases simultaneously.

The Vactrivir is reported to have been successfully tested at the preclinical and clinical trial stages, proving its safety and therapeutic efficacy. Following 42 days of observation after the vaccine was administered studies have shown good tolerance in patients and a level of safety high enough for both adults and children.

By this moment we have put together all the documents required to get the new drug candidate registered in Russia. With its level of safety and efficacy we can also talk of high export potential for the solution, Microgen CEO Kirill Gaidash said.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
COMMENT ON THIS STORY
Find Related Content

Locations:

Tags: Microgen (4) / Rostec (30) / vaccine (28) / Natsimbio (2) / rubella (0) / mumps (0) / measles (0) / Vactrivir (0) /

Latest News: Central regions
21 Sep '18 | Transport, logistics | Finance, business
19 Sep '18 | Technology & innovation | Finance, business
17 Sep '18 | Finance, business | Technology & innovation
14 Sep '18 | Energy, utilities | Technology & innovation
 

Feature stories

27 Aug '18
7 Jun '18
Russian scientists have come up with a new method of...
3 Apr '18
In regions most of European Russians will hardly ever...
Search (News archive - 21275)
Advertising
RB_Partners_Report
Advertising
Independent Software Developers Forum
Advertising
Marchmont News

Latest News

21 Sep '18
Russias Internet Initiatives Development Fund has...
19 Sep '18
Doc+, a Russian start-up, has been developing a...

Most read stories from last week

21 Sep '18
Russias Internet Initiatives Development Fund has...